Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Lenghe Zhang"'
Autor:
Lenghe Zhang, Lijuan Zhou, Yulian Wang, Chao Li, Pengjun Liao, Liye Zhong, Suxia Geng, Peilong Lai, Xin Du, Jianyu Weng
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Identifying subgroups of T-cell acute lymphoblastic leukemia (T-ALL) with poor survival will significantly influence patient treatment options and improve patient survival expectations. Current efforts to predict T-ALL survival expectations in multip
Externí odkaz:
https://doaj.org/article/f31fa1d91425449b89aeed35a32bb731
Autor:
Meifang Li, Jilong Yang, Lenghe Zhang, Sanfang Tu, Xuan Zhou, Ze Tan, Weijun Zhou, Yanjie He, Yuhua Li
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 38, Iss 1, Pp 1-15 (2019)
Abstract Background Epidermal growth factor receptor (EGFR) and epidermal growth factor receptor pathway substrate 8 (Eps8) have been widely reported to be expressed in various tumors. Eps8 is an important active kinase substrate of EGFR that directl
Externí odkaz:
https://doaj.org/article/22e6a81e5ea3451cb6c1d658b83031dc
Autor:
Yuting Wang, Lenghe Zhang, Xia Tang, Jinfeng Luo, Zhengchao Tu, Kaili Jiang, Xiaomei Ren, Fang Xu, Shingpan Chan, Yuhua Li, Zhang Zhang, Ke Ding
Publikováno v:
Translational Oncology, Vol 13, Iss 4, Pp - (2020)
GZD824 is a novel third-generation BCR-ABL inhibitor. It entered Phase II clinical trials in China and Phase Ib clinical trials in USA in 2019 for treatment of patients with resistant chronic myeloid leukemia (CML). We found that at concentrations be
Externí odkaz:
https://doaj.org/article/047a3209e1234e9ab6d6ab4b2e047e8a
Autor:
Jilong Yang, Yuhua Li, Xuan Zhou, Ze Tan, Sanfang Tu, Weijun Zhou, Meifang Li, Yanjie He, Lenghe Zhang
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 38, Iss 1, Pp 1-15 (2019)
Journal of Experimental & Clinical Cancer Research : CR
Journal of Experimental & Clinical Cancer Research : CR
Background Epidermal growth factor receptor (EGFR) and epidermal growth factor receptor pathway substrate 8 (Eps8) have been widely reported to be expressed in various tumors. Eps8 is an important active kinase substrate of EGFR that directly binds t
Autor:
Yanjie He, Yiran Chen, Xiaoling Xie, Yuxing Hu, Sanfang Tu, Honghao Zhang, Chunsheng Wang, Yuhua Li, Lenghe Zhang
Publikováno v:
Cell Death & Disease
Cell Death and Disease, Vol 11, Iss 8, Pp 1-15 (2020)
Cell Death and Disease, Vol 11, Iss 8, Pp 1-15 (2020)
Utilizing oxidative stress has recently been regarded as a potential strategy for tumor therapy. The NUAK family SNF1-like kinase 1 (NUAK1) is a critical component of the antioxidant defense system and is necessary for the survival of tumors. Therefo
Autor:
Zhao Liang, Jingwen Du, Chaoyang Song, Lenghe Zhang, Rui Huang, Yanjie He, Chunyan Yue, Xuan Zhou, Lung-Ji Chang, Peihua Cao, Zhenling Guo, Jilong Yang, Sanfang Tu, Yuchen Li, Lan Deng, Yuhua Li
Publikováno v:
American Journal of Hematology. 94
Autor:
Lenghe Zhang, Ke Ding, Xia Tang, Xiaomei Ren, Shingpan Chan, Kaili Jiang, Fang Xu, Zhengchao Tu, Yuting Wang, Zhang Zhang, Yuhua Li, Jinfeng Luo
Publikováno v:
Translational Oncology
Translational Oncology, Vol 13, Iss 4, Pp-(2020)
Translational Oncology, Vol 13, Iss 4, Pp-(2020)
GZD824 is a novel third-generation BCR-ABL inhibitor. It entered Phase II clinical trials in China and Phase Ib clinical trials in USA in 2019 for treatment of patients with resistant chronic myeloid leukemia (CML). We found that at concentrations be